NOT FOR DISTRIBUTION
Header cover image

Market Cap

CA$120.0m

Last Updated

2021/05/13 00:13 UTC

Data Sources

Company Financials +

Executive Summary

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. More Details


Snowflake Analysis

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Spectral Medical's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: EDT is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: EDT's weekly volatility (8%) has been stable over the past year.


Market Performance


7 Day Return

-9.4%

EDT

-8.2%

CA Biotechs

-0.8%

CA Market


1 Year Return

-30.4%

EDT

-26.3%

CA Biotechs

38.7%

CA Market

Return vs Industry: EDT matched the Canadian Biotechs industry which returned -29.9% over the past year.

Return vs Market: EDT underperformed the Canadian Market which returned 36.3% over the past year.


Shareholder returns

EDTIndustryMarket
7 Day-9.4%-8.2%-0.8%
30 Day-15.8%-13.7%0.2%
90 Day-29.4%-26.7%5.5%
1 Year-30.4%-30.4%-26.3%-26.3%43.3%38.7%
3 Year62.7%62.7%-3.9%-3.9%27.3%15.2%
5 Year-50.0%-50.0%11.3%11.3%57.2%33.6%

Long-Term Price Volatility Vs. Market

How volatile is Spectral Medical's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Spectral Medical undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Spectral Medical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Spectral Medical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Future Growth

How is Spectral Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

62.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EDT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.5%).

Earnings vs Market: EDT is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: EDT's is expected to become profitable in the next 3 years.

Revenue vs Market: EDT's revenue (59.4% per year) is forecast to grow faster than the Canadian market (6.5% per year).

High Growth Revenue: EDT's revenue (59.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if EDT's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Spectral Medical performed over the past 5 years?

12.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EDT is currently unprofitable.

Growing Profit Margin: EDT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: EDT is unprofitable, but has reduced losses over the past 5 years at a rate of 12.3% per year.

Accelerating Growth: Unable to compare EDT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EDT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-15.5%).


Return on Equity

High ROE: EDT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Financial Health

How is Spectral Medical's financial position?


Financial Position Analysis

Short Term Liabilities: EDT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: EDT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: EDT is debt free.

Reducing Debt: EDT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: EDT has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: EDT has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 38.3% each year


Dividend

What is Spectral Medical current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate EDT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate EDT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if EDT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if EDT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of EDT's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.1yrs

Average management tenure


CEO

Chris Seto

0.083

Tenure

CA$391,022

Compensation

Mr. Chris Seto has been the Chief Financial Officer of Spectral Medical Inc. since August 2, 2019 and also has been its Chief Operating Officer since June 4, 2020. He has been Chief Executive Officer of Sp...


CEO Compensation Analysis

Compensation vs Market: Chris's total compensation ($USD323.24K) is above average for companies of similar size in the Canadian market ($USD156.15K).

Compensation vs Earnings: Insufficient data to compare Chris's compensation with company performance.


Leadership Team

Experienced Management: EDT's management team is considered experienced (4.1 years average tenure).


Board Members

Experienced Board: EDT's board of directors are considered experienced (6.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.6%.


Top Shareholders

Company Information

Spectral Medical Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Spectral Medical Inc.
  • Ticker: EDT
  • Exchange: TSX
  • Founded: 1991
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CA$120.046m
  • Shares outstanding: 250.10m
  • Website: https://www.spectraldx.com

Number of Employees


Location

  • Spectral Medical Inc.
  • 135 The West Mall
  • Unit 2
  • Toronto
  • Ontario
  • M9C 1C2
  • Canada

Listings


Biography

Spectral Medical Inc. focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapi...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/13 00:13
End of Day Share Price2021/05/12 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.